ClinicalTrials.gg
RecruitingNCT05106972Updated Nov 4, 2021

Umbilical Cord Mesenchymal Stem Cell Transplantation for Decompensated Hepatitis B Cirrhosis

An interventional study of UC-MSC infusion in Liver Cirrhosis, sponsored by Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.. Recruiting at 1 site in China. Open to participants aged 20 Years to 60 Years. Per ClinicalTrials.gov, last updated 2021-11-04.

Sponsored by Asia Stem Cell Regenerative Pharmaceutical Co., Ltd. · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Dec 2024, 1 year 10 months ago, but the record still lists the study as recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
30
Allocation
Not applicable
Ages
20 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 214 studies in Liver Cirrhosis with a site in China — 65 open to participants now, 73 under way, 4 of them phase 3. Liver Cirrhosis · China.

Planned enrollment
107th of 127
30 · median 120
Started
2021
with 12 others
No phase
61 of 214
26 open now
Primary completion
2024-12
later than 6 of 72 live
Registered
121st of 214
by date

Among the 214 studies in Liver Cirrhosis with a site in China, this one is the 107th largest by planned enrollment of the 127 interventional ones that give a count, is one of 13 that started in 2021, is one of 61 with no phase, reaches primary completion later than 6 of the 72 other live ones, and was the 121st registered.

Liver Cirrhosis

1,301 studies on the registry are indexed under Liver Cirrhosis; 341 are open to participants now.

Browse Liver Cirrhosis studies →

Open to participants now

65 of the 214 studies in Liver Cirrhosis with a site in China are open now. Recruiting first, the newest first:

60 more — sign in →

All 65 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 208 Liver Cirrhosis studies recruiting now, 101 (49%) set no upper age limit and 66 (32%) stop at 75 or younger; 12 take children under 18; 25 take healthy volunteers.

This study: 20 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 214 studies in Liver Cirrhosis with a site in China, or all of them as a file.
02

Study summary

This study aims to evaluate the safety and clinical efficacy of umbilical cord mesenchymal stem cell transplantation for decompensated hepatitis B cirrhosis.

03

Conditions studied

  • Liver Cirrhosis

Browse trials for

04

Who can participate

Ages eligible
20 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Aged between 20 and 60 (male or female)
  • Diagnosed chronic decompensated cirrhosis with a course of more than 5 years
  • Not suitable for liver transplantation or there is no donor liver source
  • No serious bleeding tendency or active bleeding
  • No hepatic encephalopathy
  • After strict medical conservative treatment for more than 6 months, there was no relief of symptoms or significant improvement of quality of life score
  • Subjects voluntarily participate in this study and sign

Exclusion criteria

Exclusion Criteria:

  • Be less than 20 years old or more than 60 years old
  • Cirrhosis caused by other causes such as alcoholic hepatitis, virus and hepatitis
  • Found liver malignant tumor or the family history of liver malignant tumor in the third generation of their direct relatives
  • Patients with hypersplenism who need splenectomy
  • History of tumors in other organs
  • PT prolongation is greater than 3 seconds
  • Use of human serum albumin within 3 weeks prior to clinical registration
  • upper gastrointestinal bleeding events occurred within 4 weeks before clinical registration
  • Spontaneous peritonitis
  • Active infection (viral or bacterial)
  • Pregnant or lactating women
  • The researcher considers it inappropriate to participate in this study
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    UC-MSC infusion

    UC-MSC infusion by intravenus, 1\*10\^8 cells/dose, 2 doses (apart from 24weeks)

    Drug: UC-MSC infusion

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Participants with abnormal Total bilirubin

    Time frame: Changes from baseline to 72 weeks

  2. Number of Participants with abnormal albumin

    Time frame: Changes from baseline to 72 weeks

  3. Ishak Inflammation Rating System

    Time frame: Changes from baseline to 72 weeks

  4. Ishak Fibrosis Score

    Time frame: Changes from baseline to 72 weeks

Secondary outcomes

  1. Overall survival (OS)

    Time frame: Changes from baseline to 72 weeks

  2. HBV-DNA

    Time frame: Changes from baseline to 72 weeks

  3. incidence of liver cancer

    Time frame: Changes from baseline to 72 weeks

  4. Number of Participants with abnormal immunoglobulin

    Time frame: Changes from baseline to 72 weeks

  5. portal vein flow rate

    Time frame: Changes from baseline to 72 weeks

  6. portal vein width

    Time frame: Changes from baseline to 72 weeks

  7. abdominal volume

    Time frame: Changes from baseline to 72 weeks

  8. Number of Participants with abnormal coagulation function

    Time frame: Changes from baseline to 72 weeks

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Dec 2021; primary completion for Dec 2024, 36 months later.

Of 215 interventional studies with no phase under Liver Cirrhosis, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 54. This study's planned 36 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2021
First posted
Nov 4, 2021
StartEst.
Dec 1, 2021
Primary completionEst.
Dec 31, 2024
CompletionEst.
Dec 31, 2025
Last update
Nov 4, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 4, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05106972
Lead sponsor
Asia Stem Cell Regenerative Pharmaceutical Co., Ltd.
Responsible party
Sponsor
First posted
Nov 4, 2021
Start date
Dec 1, 2021 (estimated)
Primary completion
Dec 31, 2024 (estimated)
Completion
Dec 31, 2025 (estimated)
Last update
Nov 4, 2021

Study contacts

Xiaoxi Huang, PHD
Contact
huangxiaoxi@xibaozhiliao.cn
86-0898-66151200

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Solizmestrocel

Start the discussion